At DBMR, we are continuously striving to become one of the most trusted companies in the world, uniquely positioned to provide emerging healthcare technology market intelligence solutions and market research reports for- Medical Devices, Healthcare IT & Services, Life Sciences & Biotech, and Emerging Healthcare Technologies, covering the entire industry spectrum.

Cord blood banking involves storage of cord blood extracted from umbilical cord and placenta after birth. This cord blood can be used in the treatment of number of diseases such as cancers, blood disorders, metabolic disorders and many others. Cord blood stem cell is booming in medicine industry as regenerative medicine because of its importance in treating around 80 diseases.

Cord blood banks are of two types available in India such as, public or private banks. Private Banks are also called as family bank and they stores cord blood for autologous use. These banks charge yearly fees for storing cord blood of an individual. The cord blood stored in private banks is only for the donor people not for universal people. In public banks, it costs parents nothing to donate (no fees required for collection, processing and storage) and can be accessed universally by the people as per their need and hence it is also called as non-profit organization. For instance, Jeevan, a public cord blood bank which collects, process and stores cord blood but does not charge the donor which ultimately shows that the organization is not earning any profit.

India cord stem cell banking market is projected to register a healthy CAGR of 12.6% in the forecast period of 2019 to 2026.

Segmentation: India Cord Stem Cell Banking Market

India cord stem cell banking market is segmented into notable five segments and which are source, application, mode of treatment, service type and cord blood banking.

On the basis of source, the market is segmented into umbilical cord, placenta, amniotic sac and amniotic fluid.

In August 2017, Lifecell launched collection kit, an improved version of umbilical cord-stem cell. The kit is made up of stainless steel, which provides maximum protection to the sample and maintains low temperature to keep efficiency of sample. The kit is launched for the better transport of the stem cell right from the hospitals to the cryo-banks. This product launched is the novel value addition to the company’s’ services for better sample handling.

In February 2013, Reliance plans to expand triple stem cell units, almost three times capacity of its stem-cell enriched cord blood repository to close to 10,000 cell units. The company aim to scale it up to 30,000 cell units over a period of time.

On the basis of mode of treatment, the market is segmented into allogeneic and autologous.

In July 2014, Cordlife Group announced collaboration with China Cord Blood Corporation to help patients over Hong Kong, Singapore, PRC, Indonesia, India and Philippines to find out suitable match of cord blood unit for cell therapies.

On the basis of service type, the market is segmented into sample collection and transportation, sample processing, sample analysis and sample preservation and storage.

In November 2016, Mycord introduced a new concept, revolutionary private umbilical cord blood banking. All cord blood units are stored in this bank as part of private banking and this banking allows a person to access only their own cord blood for the treatment purpose. This banking helped the market in order to increase revenue because private banks charge fees for each service required in cord blood banking.

On the basis of cord blood banking, the market is segmented into private cord blood banks and public cord blood banks.

In March 2017, Lifecell launched Baby Cord Share. It is a community stem cell banking that fulfils the need of people and contains large inventory of stem cells in India. Baby Cord Share provides unique benefits of both private as well as public banks. This service was launched to raise the chances of finding a matching donor.

In November 2016, Cordlife Group accepted accreditation from College of American Pathologists for its majority owned subsidiaries, present in Hong Kong Screening Centre Limited and Cordlife Sciences (India) Pvt. Ltd.

In February 2013, Reliance plans to expand triple stem cell units, almost three times capacity of its stem-cell enriched cord blood repository to close to 10,000 cell units. The company aim to scale it up to 30,000 cell units over a period of time.

Industry Coverage

DBMR works across the globe in multiple industries which equip us with knowledge across verticals and provide our clients with insights not only from their industry but how other industries will impact their ecosystem.

Regional Coverage

Coverage of Data Bridge is not restricted to developed or emerging economies. We work across the globe covering the largest array of countries where no other market research or business consulting firm has ever conducted research; creating growth opportunities for our clients in areas which are still unknown.

Technology Coverage

In today’s world, technology drives the market sentiment, so our vision is to provide our clients insights not only for developed technologies but upcoming and disrupting technological changes throughout the product lifecycle by enabling them with unforeseen opportunities in the market which will create disruption in their industry. This leads to innovation and our clients to come out as winners.

Goal Oriented Solutions

DBMR goal is to help our clients achieve their goals through our solutions; hence we formatively create the most appropriate solutions for our client needs, saving time and efforts for them to drive their grand strategies.

Unparallel Analyst Support

Our analysts take pride in our clients’ success. Unlike others, we believe in working along our clients to achieve their goals with 24 hours analyst support determining the correct needs and inspire innovation through service